Replies to post #17 on Sol Gel Technologies Ltd (SLGL)

[midastouch017]

Bvxv - here is latest from Mar 19th
report. So the results are year end and not Q2

True. But I am referring to :

Analysis of the data is ongoing, and the clinical study report (CSR) is expected in Q2 2020.

https://www.prnewswire.com/il/news-releases/preliminary-data-from-nihniaid-sponsored-phase-2-clinical-trial-of-biondvaxs-m-001-universal-influenza-vaccine-candidate-validates-results-of-previous-clinical-trials-300999644.html

Of course “Topline results will be available before the end of 2020, but this is for Phase 3

[midastouch017]

Good listing - you did not list RDHL - then we share 3 of them.

Israel comes with great technology and success but stock market success is different story.

I am waiting for RDHL to come out of Red to get at least one success.

Sad to say, take any US company and an Israeli, the
Israeli will always be at some price disadvantage, all
other indicators being the same.

Myself i prefer the dual listed companies, i get double
SEC safety standards. (not that it helps if the company
is not successful)

BVXV used to be dual traded but decided to focus on the US
market only.

[midastouch017]

I get it, there is a slight mixup:

from https://www.prnewswire.com/il/news-releases/preliminary-data-from-nihniaid-sponsored-phase-2-clinical-trial-of-biondvaxs-m-001-universal-influenza-vaccine-candidate-validates-results-of-previous-clinical-trials-300999644.html


there are 2 subjects:

1/ preliminary data from the Phase 2 clinical trial of BiondVax's M-001 universal influenza vaccine candidate have been published. The trial was supported by the U.S. National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH). The primary objectives of the trial were to assess safety and T-cell responses to M-001. The data, which are consistent with results of previous clinical trials of M-001, indicate that both primary objectives were achieved. Analysis of the data is ongoing, and the clinical study report (CSR) is expected in Q2 2020.


2/In parallel, BiondVax's pivotal, clinical efficacy, Phase 3 trial in Europe, involving 12,463 older adults, is ongoing. Results of that trial are expected by the end of 2020.